Assessing the effect of PRP addition to facial micro-lipofilling for patients suffering from Scleroderma: A prospective routine care analysis.

Humans Female Middle Aged Prospective Studies Scleroderma, Systemic / surgery Face / surgery Mouth Platelet-Rich Plasma Treatment Outcome
Autologous adipose tissue Mouth Handicap In Systemic sclerosis Scale (MHISS) Plasma Riche en Plaquettes Platelet-Rich-Plasma Sclérodermie systémique Systemic sclerosis Tissu adipeux autologue

Journal

Annales de chirurgie plastique et esthetique
ISSN: 1768-319X
Titre abrégé: Ann Chir Plast Esthet
Pays: France
ID NLM: 8305839

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 25 04 2022
revised: 20 07 2022
accepted: 27 07 2022
medline: 14 4 2023
pubmed: 21 8 2022
entrez: 20 8 2022
Statut: ppublish

Résumé

Combining fat graft with platelet derived products is now common practice in regenerative surgery. We proposed to assess the safety and efficacy of Platelet-Rich Plasma (PRP) addition to a micro-lipofilling protocol for facial treatment of patients suffering from Systemic Sclerosis (SSc). Main objective was to evaluate the improvement of the Mouth Handicap In Systemic Sclerosis (MHISS) scale score at 6 months post-therapy. Included SSc patients had a MHISS score equal or up to 20. Surgery was performed under general anesthesia. Micro-fat and PRP (CCA-NA from DEPA Classification) were mixed in a 70/30 ratio, before injection in peri-oral sites according to a specific protocol. Efficacy criteria were recorded at baseline, 3 and 6 months. Moreover, we compared this cohort (current study) to a former (2015) non-enriched micro-lipofilling cohort in the same indication, using the same protocol. Thirteen women patients with mean age of 53.2 years (±14.3) have been included. At baseline, mean MHISS score was 29.5 (±8.7) and significantly decreased to 22.5 (±7.8) at 6 months (P=0.016), corresponding to a 22.0% of improvement from baseline, with a mean decrease of 6.5 points (±7.5) at 6 months. Patients received a mean volume of 30.8ml PRP-micro-fat (±8.1ml). PRP addition appeared beneficial, however, controlled studies are required to determine its superiority to facial micro-lipofilling.

Sections du résumé

BACKGROUND BACKGROUND
Combining fat graft with platelet derived products is now common practice in regenerative surgery. We proposed to assess the safety and efficacy of Platelet-Rich Plasma (PRP) addition to a micro-lipofilling protocol for facial treatment of patients suffering from Systemic Sclerosis (SSc).
OBJECTIVE OBJECTIVE
Main objective was to evaluate the improvement of the Mouth Handicap In Systemic Sclerosis (MHISS) scale score at 6 months post-therapy.
METHOD METHODS
Included SSc patients had a MHISS score equal or up to 20. Surgery was performed under general anesthesia. Micro-fat and PRP (CCA-NA from DEPA Classification) were mixed in a 70/30 ratio, before injection in peri-oral sites according to a specific protocol. Efficacy criteria were recorded at baseline, 3 and 6 months. Moreover, we compared this cohort (current study) to a former (2015) non-enriched micro-lipofilling cohort in the same indication, using the same protocol.
RESULTS RESULTS
Thirteen women patients with mean age of 53.2 years (±14.3) have been included. At baseline, mean MHISS score was 29.5 (±8.7) and significantly decreased to 22.5 (±7.8) at 6 months (P=0.016), corresponding to a 22.0% of improvement from baseline, with a mean decrease of 6.5 points (±7.5) at 6 months. Patients received a mean volume of 30.8ml PRP-micro-fat (±8.1ml).
CONCLUSION CONCLUSIONS
PRP addition appeared beneficial, however, controlled studies are required to determine its superiority to facial micro-lipofilling.

Identifiants

DOI: 10.1016/j.anplas.2022.07.016 PMID: 35987670
pubmed: 35987670
pii: S0294-1260(22)00118-2
doi: 10.1016/j.anplas.2022.07.016
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

152-161

Informations de copyright

Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Auteurs

M Abellan Lopez (M)

Plastic Surgery Department, La Conception Hospital, AP-HM, 13005 Marseille, France; Aix Marseille University, INSERM, INRA, C2VN, 13005 Marseille, France. Electronic address: maxime.abellanlopez@gmail.com.

C Philandrianos (C)

Plastic Surgery Department, La Conception Hospital, AP-HM, 13005 Marseille, France. Electronic address: cecile.philandrianos@ap-hm.fr.

A Daumas (A)

Internal Medicine Department, Assistance Publique Hôpitaux de Marseille (AP-HM), Aix-Marseille University, 13005 Marseille, France; Aix Marseille University, INSERM, INRA, C2VN, 13005 Marseille, France. Electronic address: aurelie.daumas@ap-hm.fr.

M Velier (M)

Cell Therapy Department, Hôpital de la Conception, AP-HM, INSERM CIC BT 1409, 13005 Marseille, France; Aix Marseille University, INSERM, INRA, C2VN, 13005 Marseille, France. Electronic address: melanie.velier@ap-hm.fr.

R Arcani (R)

Aix Marseille University, INSERM, INRA, C2VN, 13005 Marseille, France. Electronic address: robin.arcani@ap-hm.fr.

E Jouve (E)

Service de Pharmacologie Clinique et Pharmacovigilance, Assistance Publique Hôpitaux de Marseille (AP-HM), CIC-CPCET, 13005 Marseille, France. Electronic address: elisabeth.jouve@ap-hm.fr.

C Jaloux (C)

Plastic Surgery Department, La Conception Hospital, AP-HM, 13005 Marseille, France. Electronic address: charlotte.jaloux@ap-hm.fr.

B Bertrand (B)

Plastic Surgery Department, La Conception Hospital, AP-HM, 13005 Marseille, France. Electronic address: baptiste.bertrand@ap-hm.fr.

J Magalon (J)

Cell Therapy Department, Hôpital de la Conception, AP-HM, INSERM CIC BT 1409, 13005 Marseille, France; Aix Marseille University, INSERM, INRA, C2VN, 13005 Marseille, France. Electronic address: jeremy.magalon@ap-hm.fr.

F Dignat-George (F)

Cell Therapy Department, Hôpital de la Conception, AP-HM, INSERM CIC BT 1409, 13005 Marseille, France; Aix Marseille University, INSERM, INRA, C2VN, 13005 Marseille, France. Electronic address: francoise.dignat-george@univ-amu.fr.

B Granel (B)

Internal Medicine Department, Assistance Publique Hôpitaux de Marseille (AP-HM), Aix-Marseille University, 13005 Marseille, France. Electronic address: brigitte.granel@ap-hm.fr.

D Casanova (D)

Plastic Surgery Department, La Conception Hospital, AP-HM, 13005 Marseille, France. Electronic address: dominique.casanova@ap-hm.fr.

F Sabatier (F)

Cell Therapy Department, Hôpital de la Conception, AP-HM, INSERM CIC BT 1409, 13005 Marseille, France; Aix Marseille University, INSERM, INRA, C2VN, 13005 Marseille, France. Electronic address: florence.sabatier@ap-hm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Assessing the effect of PRP addition to facial...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Assessing the effect of PRP addition to facial...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Assessing the effect of PRP addition to facial...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Sclérodermie systémique › Assessing the effect of PRP addition to facial...
questionsmedicales.fr › Régions du corps › Tête › Face › Assessing the effect of PRP addition to facial...
questionsmedicales.fr › Système stomatognathique › Bouche › Assessing the effect of PRP addition to facial...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Sang › Plasma sanguin › Plasma riche en plaquettes › Assessing the effect of PRP addition to facial...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Assessing the effect of PRP addition to facial...